Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
CEO ReviewCompany Review

The Silicon Review Asia

Natco launches cut-price versions of cancer drug in India

Natco launches cut-price versions of cancer drug in India

Hyderabad-based pharma company Natco Pharma launched a new and cut-price version of ibrutinib which is an anti-cancerous drug under its own brand name called Ibrunat. The patent of this particular drug was held by a company named Pharmacyclics for more than four years in India. But the latter company was acquired by US giant AbbVie. So now, the marketing right for ibrutinib is held by Natco and Johnson & Johnson.

Ibrutinib is used to treat patients with leukemia and other similar types of cancer. It is considered as one of the most used oncogenic drugs. Natco in a recent press meet has announced that the firm is all set to launch the drug under its own brand name by March 2020. It is learned that the Indian drug maker has already dispatched the drug in distribution channels. The Natco drug will cost at approximately INR 38000 per month as opposed to the INR 4 lakh course of the innovator. A patient is expected to take 4 tablets each day.

Natco’s latest move pertaining to the launch of the drug is consistent. Natco's product will be cheaper when compared to the other drugs which were available prior to the market. It is more effective and also is recommended by most of the oncologists in India and other countries too.


Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...